Trials / Recruiting
RecruitingNCT07093801
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Real-world Experience of Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, National, Multicenter, Prospective Cohort Study (PLU4REAL).
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
Conditions
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2029-03-30
- Completion
- 2029-03-30
- First posted
- 2025-07-30
- Last updated
- 2026-02-20
Locations
32 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT07093801. Inclusion in this directory is not an endorsement.